Skip to Content

Gadoversetamide Pregnancy and Breastfeeding Warnings

Gadoversetamide is also known as: OptiMARK

Gadoversetamide Pregnancy Warnings

Gadoversetamide has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. There are no controlled data in human pregnancy. Gadoversetamide is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.

See references

Gadoversetamide Breastfeeding Warnings

There are no data on the excretion of gadoteridol into human milk. The manufacturer recommends that women should discontinue nursing and discard breast milk up to 72 hours after gadoversetamide administration.

See references

References for pregnancy information

  1. "Product Information. OptiMARK (gadoversetamide)." Mallinckrodt Medical Inc, St. Louis, MO.

References for breastfeeding information

  1. "Product Information. OptiMARK (gadoversetamide)." Mallinckrodt Medical Inc, St. Louis, MO.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide